Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

赛诺菲向赛诺菲创投追加6.25亿美元，以加速生物技术和数字健康创新领域的投资。

The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategy

该基金将仍然专注于赛诺菲的关键领域：免疫学、罕见病、神经学和疫苗，支持早期创新和符合公司长期战略的新兴机会。

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

赛诺菲风险投资通过领导和参与先锋医疗公司的私人融资轮次来推动创新。

Paris, September 24, 2025.

巴黎，2025年9月24日。

Sanofi Ventures

赛诺菲风险投资

has announced an additional $625 million multi-year capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion. This new commitment to the evergreen venture fund builds on more than a decade of investing in innovative biotech and digital health companies that align with Sanofi’s long-term growth ambitions..

宣布赛诺菲追加6.25亿美元的多年期资本承诺，使其管理的总资产超过14亿美元。这项对永续风险基金的新承诺建立在十多年来投资于与赛诺菲长期增长目标相符的创新生物技术和数字健康公司的基础之上。

“This new, significant capital commitment reflects our strong belief that some of the most important medical breakthroughs begin in early-stage companies. With a proven track record of strategic wins and successful exits, Sanofi Ventures has become a powerful engine for scientific progress and strategic growth,” .

“这项新的、重要的资本承诺反映了我们坚信一些最重要的医学突破始于早期公司。凭借经过验证的战略成功和成功退出的记录，赛诺菲风险投资已成为科学进步和战略增长的强大引擎。”

said

说

Paul Hudson

保罗·哈德森

, Chief Executive Officer at Sanofi

赛诺菲首席执行官

. “By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.”

“通过加强我们的投资能力，我们正在加速实现提供改善人们生活的下一代疗法，同时在医疗保健生态系统中建立有价值的合作伙伴关系。”

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in top-tier biotech and artificial intelligence/digital health companies that focus on helping patients and transforming the practice of medicine. Since its inception in 2012, the fund has deployed over $800 million across more than 70 innovative companies in biotech and digital health.

赛诺菲风投是赛诺菲的企业风险投资部门，专注于投资一流的生物技术和人工智能/数字健康公司，这些公司致力于帮助患者并变革医疗实践。自2012年成立以来，该基金已在生物技术和数字健康领域超过70家创新公司中投入超过8亿美元。

The team leads investments across all stages of the private company lifecycle, from seed to crossover, serves on boards, and participates in IPOs. Sanofi Ventures maintains a diverse, globally distributed portfolio of companies advancing innovation around the world..

该团队在私营公司生命周期的所有阶段（从种子轮到交叉轮）领投，并参与董事会工作和首次公开募股。赛诺菲风投公司保持着一个多元化、全球分布的公司组合，这些公司在世界各地推动创新。

'The increased capital commitment enables us to deepen our role as a leading strategic investor in breakthrough science and digital innovation. Our global portfolio spans the full company lifecycle from seed-stage through IPO participation, demonstrating the long-term value we bring to both entrepreneurs and Sanofi,” .

“增加的资本投入使我们能够加深作为突破性科学和数字创新领域领先战略投资者的角色。我们的全球投资组合覆盖了从种子阶段到首次公开募股参与的整个公司生命周期，展示了我们为创业者和赛诺菲带来的长期价值。”

said

说

Jason P. Hafler

杰森·P·哈弗勒

, PhD, Managing Director at Sanofi Ventures. “

博士，赛诺菲风险投资公司董事总经理。“

The strong performance of our fund, including three realized exits in 2024 from companies with a combined acquisition value of $3.25 billion, validates our evergreen structure and approach to identifying and supporting companies that are at the forefront of medical innovation.'

我们基金的强劲表现，包括在2024年通过三笔已实现的退出，涉及公司合计收购价值达32.5亿美元，这验证了我们的常青结构以及识别和支持处于医疗创新前沿公司的方法。

Sanofi Ventures' expanded capital commitment comes at a time when access to early-stage funding has become more limited across the biotech sector, positioning the fund to play a crucial role in advancing healthcare innovation. By providing essential financial backing and strategic support, the fund is helping to bridge the gap for promising startups, enabling them to advance potentially life-changing therapies through key development milestones.

赛诺菲创投在生物技术领域早期融资渠道变得更加有限之际增加了资本投入，这使得该基金在推动医疗创新方面发挥了关键作用。通过提供必要的财务支持和战略协助，该基金帮助有潜力的初创企业弥合差距，使它们能够推动可能改变生命的疗法跨越关键的发展里程碑。

This strategy not only strengthens Sanofi's pipeline of future innovations but also reinforces the company's position as a leading catalyst for breakthrough science in healthcare..

这一战略不仅加强了赛诺菲未来创新的渠道，也巩固了该公司作为医疗保健领域突破性科学的领先催化剂的地位。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现令人瞩目的增长。我们运用对免疫系统的深刻理解，发明能够治疗和保护全球数百万人的药物和疫苗，并通过创新的研发管线，有望使数百万人进一步受益。

Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time..

我们的团队以一个目标为指导：我们追逐科学的奇迹以改善人们的生活；这激励我们通过应对当今最紧迫的医疗、环境和社会挑战，推动进步，为我们服务的人们和社区带来积极的影响。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在 EURONEXT（欧元区证券交易所）上市，股票代码为 SAN；同时在 NASDAQ（纳斯达克）上市，股票代码为 SNY。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·根杜尔@赛诺菲.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

evan.berland@sanofi.com

Léo Le Bourhis

莱奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Léa Ubaldi

莱娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库兹克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

托马斯.拉森@赛诺菲.com

Alizé Kaisserian

阿利泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Felix Lauscher

费利克斯·劳舍尔

| +1 908 612 7239 |

| +1 908 612 7239 |

felix.lauscher@sanofi.com

felix.lauscher@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@赛诺菲.com

Nathalie Pham

纳塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

纳塔莉·冯·赛诺菲公司

Tarik Elgoutni

塔里克·埃尔古特尼

| +1 617 710 3587 |

| +1 617 710 3587 |

tarik.elgoutni@sanofi.com

塔里克·埃尔古蒂@赛诺菲.com

Thibaud Châtelet

蒂博·沙泰莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Sanofi forward looking statement

赛诺菲前瞻性声明

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）定义的前瞻性陈述。前瞻性陈述并非历史事实。这些陈述包括预测和估计及其基本假设，有关未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的陈述，以及有关未来业绩的陈述。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

前瞻性声明通常可以通过“预期”、“预计”、“相信”、“打算”、“估计”、“计划”等词语和类似表述加以识别。尽管赛诺菲的管理层认为这些前瞻性声明中反映的预期是合理的，但投资者应注意，前瞻性信息和声明受到各种风险和不确定因素的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与前瞻性信息和声明中明示、暗示或预测的内容存在重大差异。

These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and com.

这些风险和不确定性包括但不限于研发、未来临床数据及分析（包括上市后）、监管机构（如FDA或EMA）的决定，这些决定涉及是否以及何时批准任何可能为这些候选产品提交的药物、器械或生物制品申请，还包括他们关于标签和其他可能影响这些候选产品的可用性或商业潜力的事宜的决定，以及候选产品即便获得批准也可能无法商业成功的事实，未来的批准和商业化进程等。

All trademarks mentioned in this press release are the property of the Sanofi.

本新闻稿中提到的所有商标均为赛诺菲的财产。

Attachment

附件

Press Release

新闻稿

Share

分享